GU Cancer ESMO 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / gu-cancer-esmo-2024-highlights

Rahul Gosain, MD; Rohit Gosain, MD, and Petros Grivas, MD, examine recent oncology studies presented at ESMO 2024, including TiNivo-2, PEACE-3, and CONTACT-02, focusing on survival outcomes, combination therapies, and treatment efficacy in specific patient populations with metastatic disease.

1 KOL is featured in this series.

EP. 1: ESMO 2024: Updates in NIAGARA Study

Rahul Gosain, MD;Rohit Gosain, MD;Petros Grivas, MD, PhD
September 30th 2024

Panelists discuss how overall survival and event-free survival data presented at ESMO 2024 demonstrate promising outcomes in cancer treatment.

1 KOL is featured in this series.

EP. 2: Exploring Updates in TiNivo-2 From ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Petros Grivas, MD, PhD
September 30th 2024

Panelists discuss how the combination of Tivozanib plus Nivolumab from the TiNivo-2 study, along with other data presented at ESMO 2024, shows potential for improving outcomes in certain cancer treatments.

1 KOL is featured in this series.

EP. 3: Recent Updates in PEACE-3 Trial Presented at ESMO 2024

Rahul Gosain, MD;Rohit Gosain, MD;Petros Grivas, MD, PhD
September 30th 2024

Panelists discuss how the EORTC-GUCG 1333 (PEACE-3) trial, presented at ESMO 2024, illuminates key findings regarding the study population and primary endpoints in genitourinary cancer research.

1 KOL is featured in this series.

EP. 4: ESMO 2024 Trial Updates: Contact-02

Rahul Gosain, MD;Rohit Gosain, MD;Petros Grivas, MD, PhD
September 30th 2024

Panelists discuss how the CONTACT-02 study results reveal final overall survival data for patients with liver or bone metastases, providing crucial insights into treatment efficacy for these specific metastatic sites.